US Advances First Ibogaine Trials
US health officials are advancing the first government funded clinical trials of ibogaine to treat opioid addiction and PTSD. The FDA has opened a public docket seeking feedback on safety rules and trial design by November 20 following a federal funding push.
The United States is advancing the first government-funded clinical trials of the psychedelic drug ibogaine to treat opioid addiction and PTSD. The initiative follows an April executive order dedicating $50 million to federal research into the compound. This marks a major regulatory shift for a Schedule I substance historically restricted due to severe cardiac risks.
